Related Experiment Video

Updated: Jun 6, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Reactivation of p53: from peptides to small molecules

Christopher J Brown1, Chit F Cheok, Chandra S Verma

  • 1p53 Laboratory (p53Lab, A*STAR), 8A Biomedical Grove, #06-06, Immunos, 138648, Singapore.

Trends in Pharmacological Sciences
|December 15, 2010
PubMed

Insights

Tumor suppressor p53 pathway inactivation affects 27 million people. Therapeutic strategies focus on reactivating p53 by stabilizing mutants or inhibiting negative regulators like MDM2/MDM4.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • The tumor suppressor protein p53 plays a critical role in preventing cancer.
  • Inactivation of p53's tumor-suppressing activity is observed in approximately 27 million individuals with tumors.
  • Pathway abrogation occurs through various mechanisms, including overexpression of negative regulators (MDM2, MDM4) or inactivation of positive regulators (ARF).

Purpose of the Study:

  • To highlight the significance of p53 pathway inactivation in cancer.
  • To discuss therapeutic strategies aimed at restoring p53 function.
  • To explore the development of small molecule approaches for p53 reactivation.

Main Methods:

  • Analysis of mechanisms leading to p53 pathway abrogation in tumors.
  • Review of therapeutic strategies targeting p53.
  • Investigation of small molecule approaches for p53 reactivation.

Main Results:

  • p53 pathway is inactivated in half of tumors due to mechanisms other than direct p53 mutation.
  • Mutations in p53, primarily in the DNA-binding domain, inactivate its transcriptional activity in the other half of tumors.
  • Peptide research has informed small molecule strategies for p53 reactivation.

Conclusions:

  • Restoring the tumor-suppressive properties of p53 is a crucial therapeutic objective.
  • Small molecule approaches, including stabilizing mutant p53 or inhibiting MDM2/MDM4, show promise for cancer therapy.
  • Targeting the p53 pathway offers a significant therapeutic avenue for a large patient population.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...